Annual report for 2021
Announcement No.: 2022019
April 2022
Section I important tips, contents and definitions
The board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee that the contents of the annual report are true, accurate and complete without false records, misleading statements or major omissions, and bear individual and joint legal liabilities.
Yao Jianer, the person in charge of the company, Zhang Jiajin, the person in charge of accounting, and Zhang Jiajin, the person in charge of accounting organization (Accounting Supervisor), declare that they guarantee the authenticity, accuracy and completeness of the financial report in this annual report.
All directors have attended the meeting of the board of directors to consider this report.
Any forward-looking statements such as future plans in the annual report do not constitute the company’s substantive commitment to investors. Investors and relevant persons should maintain sufficient risk awareness and understand the differences between plans, forecasts and commitments.
The company described the possible risks and Countermeasures in the company’s operation in Section III “management discussion and analysis”, section Xi. Prospects for the company’s future development “(IV) possible risks”, and investors are invited to pay attention and read them carefully.
The profit distribution plan approved by the board of directors is: Based on the total number of shares of the company after deducting the repurchase of shares in the special account from the total share capital of the company on the equity registration date when the distribution plan is implemented in the future, the company will distribute cash dividends of 2.50 yuan (including tax) to all shareholders for every 10 shares, give bonus shares of 0 shares (including tax), and transfer capital reserve to all shareholders for every 10 shares.
catalogue
Section I important tips, contents and definitions Section 2 company profile and main financial indicators Section III Management Discussion and Analysis Section IV corporate governance 38 Section V environmental and social responsibility 58 section VI important matters Section VII changes in shares and shareholders 67 Section VIII preferred shares 76 section IX relevant information of bonds 77 section x financial report seventy-eight
Directory of documents for future reference
1、 Financial statements containing the signatures and seals of the person in charge of the company, the person in charge of accounting work and the person in charge of accounting organization (Accounting Supervisor). 2、 The original of the audit report with the seal of the accounting firm and the signature and seal of the certified public accountant. 3、 The originals of all company documents and announcements publicly disclosed on the website designated by the CSRC during the reporting period. 4、 Other relevant information.
interpretation
Explanatory item refers to the explanatory content
The company, the company, the parent company, Tellgen Corporation(300642) refers to Tellgen Corporation(300642)
Transparent diagnosis refers to Shanghai transparent Diagnosis Technology Co., Ltd., which is a wholly-owned subsidiary of the company
Hunan toujing refers to Hunan Tellgen Corporation(300642) Technology Co., Ltd., which is a wholly-owned subsidiary of the company
Jiangxi toujing refers to Jiangxi Tellgen Corporation(300642) Technology Co., Ltd., which is a wholly-owned subsidiary of the company
Toujing Xukang refers to Shanghai toujing Xukang Medical Technology Co., Ltd., which is a holding subsidiary of the company
The controlling shareholder and actual controller refers to Yao Jianer
Lingfei group refers to Lingfei Group Co., Ltd
Rongzhen investment refers to Shanghai Rongzhen Investment Group Co., Ltd
CSRC refers to the China Securities Regulatory Commission
General meeting of shareholders refers to Tellgen Corporation(300642) general meeting of shareholders
Yuan and 10000 yuan refer to RMB yuan and 10000 yuan
IVD means in vitro diagnosis
In vitro diagnosis refers to products and services that use corresponding instruments and reagents to detect samples (blood, body fluid, tissue, etc.) and obtain clinical diagnosis information
In vitro diagnostic reagents managed according to medical devices, including those that can be used alone or in combination with instruments, instruments, equipment or systems, in the process of disease prevention, diagnosis, treatment monitoring, prognosis observation, in vitro diagnostic reagents, diagnostic reagents refer to the evaluation of health status and the prediction of genetic diseases, Reagents, kits, calibrators and quality control materials used for in vitro detection of human samples (various body fluids, cells, tissue samples, etc.)
A class of substances that can cause immune response in human and animal bodies. They can not only stimulate the immune system to produce antigen-specific immune response, form antibodies and sensitized lymphocytes, but also react with them.
It is usually a protein, but polysaccharides and nucleic acids can also be used as antigens
Antibody refers to the immunoglobulin produced by the body under the stimulation of antigen, which can specifically bind to the antigen
Human papillomavirus (HPV) refers to a kind of papillomavirus a belonging to the HPV family of milk polyposis virus. It is a spherical DNA virus, which can cause the proliferation of squamous epithelium of human skin and mucosa
Substances produced by abnormal malignant tumor cells, or substances produced by the host’s stimulation response to tumor, which can reflect the occurrence and development of tumor and monitor the response of tumor to treatment
High throughput flow fluorescence technology and flow fluorescence technology refer to a new high-throughput and high-speed biological detection method, which organically integrates multiple amplification technology, multi index joint detection technology in the field of biology and flow technology in the field of instrument manufacturing
Explanatory item refers to the explanatory content
It can be widely used in immunological analysis and nucleic acid analysis. Its main features are: the detection results of dozens of biomarkers can be obtained at one time, and the detection speed is 3-10 times that of chemiluminescence technology
A commonly used clinical marker immunoassay method. Its basic principle is that after antigen antibody reaction, chemiluminescence immunoassay technology and chemiluminescence technology, the chemiluminescence substrate emits photons through catalyst catalysis or oxidation of oxidant, and the antigenic antibody can be quantitatively determined by measuring the yield of photons
An efficient multi-target gene amplification and detection technology is developed from the basis of monochrome fluorescent PCR technology and multi-color fluorescent PCR technology. Through reasonable design, this technology can realize the effect of detecting multiple indexes in a reaction tube at the same time
The reporting period refers to the period from January 1, 2021 to December 31, 2021
The same period of last year refers to the period from January 1, 2020 to December 31, 2020
The end of the reporting period refers to December 31, 2021
Section II Company Profile and main financial indicators
1、 Company information
Stock abbreviation Tellgen Corporation(300642) stock code Tellgen Corporation(300642)
Chinese name of the company Tellgen Corporation(300642)
Chinese abbreviation of the company Tellgen Corporation(300642)
Foreign language name of the company (if any) Tellgen Corporation
Abbreviation of the company’s foreign name (if any) Tellgen
The legal representative of the company is Yao Jianer
Registered address: Building 1, No. 115, Lane 572, Bibo Road, China (Shanghai) pilot Free Trade Zone
Postal code of registered address 201203
Historical changes of the company’s registered address there was no change of registered address during the reporting period
Office address: Building 1, No. 115, Lane 572, Bibo Road, China (Shanghai) pilot Free Trade Zone
Postal code of office address 201203
Company Internet website http://www.tellgen.com./
E-mail [email protected].
2、 Contact person and contact information
Secretary of the board of directors and securities affairs representative
Name: Wang Xiaoqing, Hu Chunyang
Contact address: Building 1, No. 115, Lane 572, Bibo Road, China (Shanghai) pilot Free Trade Zone Building 1, No. 115, Lane 572, Bibo Road, China (Shanghai) pilot Free Trade Zone
Tel: 86-2150495115
